Innovation for Health - 14 February 2019
Global Investor Forum Contact
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare
Innovation for Health - Shaping the future of healthcare
Innovation for Health - Shaping the future of healthcare
Innovation for Health - Shaping the future of healthcare

Jan van de Winkel

CEO, Genmab A/S

Session

10:00 - 11:10
Plenary Program

Jan van de Winkel is President and Chief Executive Officer of Genmab, which he co-founded in February 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody therapeutics for cancer.

Dr. van de Winkel has overseen the creation and development of a number of human antibodies for the treatment of cancer and other diseases.
Genmab has two approved and marketed drugs, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of several chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, NKT-cell lymphoma, myelodysplastic syndrome, amyloidosis and solid tumors. A subcutaneous formulation of ofatumumab is in Phase III development for relapsing multiple sclerosis. Genmab has a broad pre-clinical and clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.

Dr. van de Winkel has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and patent applications. Dr. van de Winkel holds a professorship of Immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Biotech AG, member of the board of directors of LEO Pharma and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund.

Abstract

Biotechnology drives Transformation of Cancer Treatment
Biotechnology presently drives innovation in healthcare and new drug development. One of the healthcare challenges is the rising number of global deaths from cancer. This presentation addresses the changing global innovation ecosystem and focuses on the important role of immunotherapy as a new pillar of cancer care. It will highlight the unique characteristics of DARZALEX a first-in-class immunomodulatory cancer drug that has been identified as one of the medicines that may transform the BioPharma landscape in the coming years.

Henk van Houten
Royal Philips

Henk van Houten
Edwin Moses
Ablynx
Edwin Moses

Peter Paul van Benthem
Dutch Association of Medical Specialists

Peter Paul van Benthem
Niels Chavannes
LUMC
Niels Chavannes

Madelon Maurice
UMC Utrecht & Oncode Institute

Madelon Maurice
Ingmar de Gooijer
myTomorrows
Ingmar de Gooijer
Tom Miller
GreyBird Ventures
Tom Miller
Mark van Houdenhoven
Sint Maartenskliniek
Mark van Houdenhoven
Ruben Kok
Dutch Techcentre for Life Sciences
Ruben Kok
Colja Laane
Mibiton
Colja Laane

Arthur Lahr
Kiadis Pharma

Arthur Lahr
Eveliene Manten-Horst
AYA Jongvolwassen & Kanker
Eveliene Manten-Horst
Kas Maessen
NWO Grootschalig Infrastructuur
Kas Maessen
Eline Vrijland-van Beest
NightBalance
Eline Vrijland-van Beest
Jos Malda
UMC Utrecht
Jos Malda
Lucien Hordijk
Journalist
Maarten van Dongen
LabForRent
Maarten van Dongen
Kees Recourt
Mibiton Foundation
Kees Recourt

Maurits van Selms
ACTA

Maurits Selms
Marianne van der Steen
MERLN
Marianne van der Steen
Werner Verbiest
Janssen Diagnostics
Werner Verbiest
Markwin Velders
Kite Pharma
Markwin Velders
Nicolas Vergauwe
miDiagnostics
Nicolas Vergauwe

Marc Schellekens
LabHotel Rotterdam

Marc Schellekens
Bert-Arjan Millenaar
NLC The Healthtec Venture Builder
Bert-Arjan Millenaar
Phil L'Huillier
MSD
Jeff Gielen
Kadans Science Partner
Jeff Gielen
Annemiek Verkamman
HollandBIO
Ton van der Steen
Erasmus MC Medical Delta
Hans Schikan
Health~Holland
Joep de Groot
CbusineZ
Joep de Groot
Peter Hinssen
nexxworks
Sponsors & Partners
Main partner
Health~Holland
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Janssen Diagnostics - Janssen
Gold sponsor
Medical Delta
Silver sponsor
NLC The Healthtec Venture Builder
Sponsor
Kempen
Partner
Vereniging Innovatieve Geneesmiddelen
Partner
Global Investor Forum
Your logo?
Become a sponsor of Innovation for Health 2019!
© 2018 Innovation for Health